Oxford BioMedica plc: Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner

Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business

Related Keywords

Boston ,Massachusetts ,United States ,United Kingdom ,Mary Jane Elliott ,Ukand Bedford ,Stuart Paynter ,Matthew Neal ,Cara Mayfield ,Theresa Mcneely ,Arthur Tzianabos ,Oxford Biomedicabroadens ,Oxford Biomedicaand John Dawson ,Roch Doliveux ,Oxford Biomedicaanalyst ,John Dawson ,Oxford Biomedicafor ,Oxford Biomedica ,Sophia Bolhassan ,Listing Rules Of The Financial Conduct Authority ,Financial Services ,Group Board ,Nasdaq ,Oxford Biomedica Solutions ,Exchange Commission ,European Union Withdrawal ,Corporate Communications ,Homology Medicines Inc ,Consilium Strategic Communications ,Homology Medicines Established ,Homology Medicines ,Board Director ,Adeno Associated Virus ,Innovation Business ,Biomedica Solutions ,Tim Kelly ,Chief Executive Officer ,Chief Operating Officer ,Investigational New Drug ,Hart Scott Rodino Antitrust Improvements Act ,Homology Medicine ,Gene Therapy ,Chief Financial ,Strategic Communications ,Patient Advocacy ,Listing Rules ,Financial Conduct Authority ,European Union ,Prospectus Regulation Rules ,Markets Act ,Private Securities Litigation Reform Act ,Quarterly Report ,Oxford ,Biomedica ,Broadens ,Reading ,Viral ,Sector ,Offerings ,Incorporating ,Homology ,Medicines ,Stablished ,Capabilities ,Ewly ,Ormed ,Manufacturing ,Innovation ,Business ,Owner ,